|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2004-7-20
|
|
pubmed:abstractText |
Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:KruegerJulie AJA,
pubmed-author:LeonardYvonne MYM,
pubmed-author:LewisS DaleSD,
pubmed-author:LucasBobby JBJ,
pubmed-author:LyleElizabeth AEA,
pubmed-author:LyleTerry ATA,
pubmed-author:LynchJoseph JJJ,
pubmed-author:McMastersDaniel RDR,
pubmed-author:Miller-SteinCynthiaC,
pubmed-author:MorrissetteMatthew MMM,
pubmed-author:StaufferKenneth JKJ,
pubmed-author:VaccaJoseph PJP,
pubmed-author:WallaceAudrey AAA,
pubmed-author:WelshDenise CDC,
pubmed-author:WhiteRebecca BRB,
pubmed-author:WilliamsPeter DPD,
pubmed-author:WongBradley KBK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4161-4
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. matthew_morrissette@merck.com
|
|
pubmed:publicationType |
Journal Article
|
